Voltage-dependent blockade by bupivacaine of cardiac sodium channels expressed in Xenopus oocytes
Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels （VGSCs）, how these hyd...
Saved in:
| Published in | Neuroscience bulletin Vol. 30; no. 4; pp. 697 - 710 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Heidelberg
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
01.08.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1673-7067 1995-8218 1995-8218 |
| DOI | 10.1007/s12264-013-1449-1 |
Cover
| Abstract | Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels （VGSCs）, how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Navl.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacaine- triggered arrhythmia. Here, we investigated the effect of bupivacaine on Navl.5 within the clinical concentration range. The electrophysiological measurements on Navl.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltage- and concentration-dependent blockade on the peak of/Na and the half-maximal inhibitory dose was 4.51 pmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Navl.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Nay1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine. |
|---|---|
| AbstractList | Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels (VGSCs), how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Nav1.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacaine-triggered arrhythmia. Here, we investigated the effect of bupivacaine on Nav1.5 within the clinical concentration range. The electrophysiological measurements on Nav1.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltage- and concentration-dependent blockade on the peak of I Na and the half-maximal inhibitory dose was 4.51 μmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Nav1.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Nav1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine.Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels (VGSCs), how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Nav1.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacaine-triggered arrhythmia. Here, we investigated the effect of bupivacaine on Nav1.5 within the clinical concentration range. The electrophysiological measurements on Nav1.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltage- and concentration-dependent blockade on the peak of I Na and the half-maximal inhibitory dose was 4.51 μmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Nav1.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Nav1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine. Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels （VGSCs）, how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Navl.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacaine- triggered arrhythmia. Here, we investigated the effect of bupivacaine on Navl.5 within the clinical concentration range. The electrophysiological measurements on Navl.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltage- and concentration-dependent blockade on the peak of/Na and the half-maximal inhibitory dose was 4.51 pmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Navl.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Nay1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine. Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels (VGSCs), how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Na v 1.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacaine-triggered arrhythmia. Here, we investigated the effect of bupivacaine on Na v 1.5 within the clinical concentration range. The electrophysiological measurements on Na v 1.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltage- and concentration-dependent blockade on the peak of I Na and the half-maximal inhibitory dose was 4.51 μmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Na v 1.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Na v 1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine. Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels (VGSCs), how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Nav1.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacaine-triggered arrhythmia. Here, we investigated the effect of bupivacaine on Nav1.5 within the clinical concentration range. The electrophysiological measurements on Nav1.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltage- and concentration-dependent blockade on the peak of I Na and the half-maximal inhibitory dose was 4.51 μmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Nav1.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Nav1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine. Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels (VGSCs), how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Nav1.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacaine-triggered arrhythmia. Here, we investigated the effect of bupivacaine on Nav1.5 within the clinical concentration range. The electrophysiological measurements on Nav1.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltage- and concentration-dependent blockade on the peak of I Na and the half-maximal inhibitory dose was 4.51 μmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Nav1.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Nav1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine. |
| Author | Heng Zhang Hui Ji Zhirui Liu Yonghua Ji Xinmin You Gang Ding Zhijun Cheng |
| AuthorAffiliation | Xinhua Hospital Chongming, Shanghai Jiaotong University School of Medicine, Shanghai 202150, China Xinhua Translational Institute for Cancer Pain, Shanghai 202150, China Lab of Neuropharmacology and Neurotoxicology, Shanghai University, Shanghai 200444, China |
| Author_xml | – sequence: 1 givenname: Heng surname: Zhang fullname: Zhang, Heng organization: Lab of Neuropharmacology and Neurotoxicology, Shanghai University – sequence: 2 givenname: Hui surname: Ji fullname: Ji, Hui organization: Xinhua Hospital (Chongming), Shanghai Jiaotong University School of Medicine, Xinhua Translational Institute for Cancer Pain – sequence: 3 givenname: Zhirui surname: Liu fullname: Liu, Zhirui organization: Lab of Neuropharmacology and Neurotoxicology, Shanghai University – sequence: 4 givenname: Yonghua surname: Ji fullname: Ji, Yonghua organization: Xinhua Translational Institute for Cancer Pain, Lab of Neuropharmacology and Neurotoxicology, Shanghai University – sequence: 5 givenname: Xinmin surname: You fullname: You, Xinmin organization: Xinhua Hospital (Chongming), Shanghai Jiaotong University School of Medicine, Xinhua Translational Institute for Cancer Pain – sequence: 6 givenname: Gang surname: Ding fullname: Ding, Gang email: ddgang@hotmail.com organization: Xinhua Hospital (Chongming), Shanghai Jiaotong University School of Medicine, Xinhua Translational Institute for Cancer Pain – sequence: 7 givenname: Zhijun surname: Cheng fullname: Cheng, Zhijun email: zj.cheng@hotmail.com organization: Xinhua Hospital (Chongming), Shanghai Jiaotong University School of Medicine, Xinhua Translational Institute for Cancer Pain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25008571$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU1v1DAQhiNURD_gB3BBFicuAY8d2_EFCVVQkCpxAcTNcuzJrkvWTu2kZf99s9qlfBwqTh7J7zPvzDun1VFMEavqOdDXQKl6U4Ax2dQUeA1No2t4VJ2A1qJuGbRHSy0VrxWV6rg6LeWKUkkVb55Ux0xQ2goFJ5X9lobJrrD2OGL0GCfSDcn9sB5JtyXdPIYb62yISFJPnM0-WEdK8mHeELe2MeJQCP4cM5aCnoRIvmNM41xISm47YXlaPe7tUPDZ4T2rvn54_-X8Y335-eLT-bvL2gnKprrXsuk4NBa0AoHecqZ71SnOXccF63Wnnceetxpt6zsHyFF54bzWHDzr-FnF9n3nONrtrR0GM-awsXlrgJpdXmafl1nyMru8DCzQ2z00zt0GvVv2z_Y3mGwwf__EsDardGOEkEwytjR4dWiQ0_WMZTKbUBwOg42Y5mJACKCgpBKL9MWfXvcmv46xCGAvcDmVkrH_rwXUP4wLk51C2o0bhgfJQ15lcYkrzOYqzTkuJ3oQenmwW6e4ul64-xmlZJRyCZzfAUffyzQ |
| CitedBy_id | crossref_primary_10_1007_s00210_016_1231_9 crossref_primary_10_1002_chir_23698 crossref_primary_10_1016_j_jbc_2025_108387 crossref_primary_10_3389_fphar_2022_855792 crossref_primary_10_1097_ALN_0000000000000832 crossref_primary_10_1097_ALN_0000000000002180 crossref_primary_10_2147_JEP_S375349 crossref_primary_10_1007_s00894_021_04799_w |
| Cites_doi | 10.1111/j.1540-8167.2006.00411.x 10.1161/CIRCRESAHA.110.238469 10.1007/s12264-010-0122-1 10.1126/science.8085162 10.1124/mol.63.6.1398 10.1016/S0014-2999(03)01595-4 10.1016/0092-8674(95)90359-3 10.1085/jgp.81.5.613 10.1007/s12264-012-1234-6 10.2165/00002018-200225030-00002 10.1046/j.1540-8167.2001.00680.x 10.1097/00000542-198504000-00006 10.1161/CIRCRESAHA.109.198572 10.1161/01.CIR.92.10.3014 10.1016/j.rapm.2004.12.001 10.1146/annurev.bi.64.070195.002425 10.1016/j.ejphar.2006.04.025 10.1152/physrev.00024.2004 10.1097/00005344-198911000-00016 10.2174/1568026013395164 10.2147/TCRM.S1433 10.1016/S0022-3565(24)38774-9 10.1152/physrev.1992.72.suppl_4.S15 10.1124/mol.56.2.404 |
| ContentType | Journal Article |
| Copyright | Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2014 |
| Copyright_xml | – notice: Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2014 |
| DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY |
| DOI | 10.1007/s12264-013-1449-1 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Voltage-dependent blockade by bupivacaine of cardiac sodium channels expressed in Xenopus oocytes |
| EISSN | 1995-8218 |
| EndPage | 710 |
| ExternalDocumentID | 10.1007/s12264-013-1449-1 PMC5562622 25008571 10_1007_s12264_013_1449_1 662003613 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -05 -0E -56 -5G -BR -EM -SE -S~ -Y2 -~C .86 .VR 06C 06D 0R~ 0VX 0VY 123 1N0 29N 29~ 2B. 2C~ 2J2 2JN 2JY 2KG 2KM 2LR 2RA 2VQ 2~H 30V 4.4 406 408 40D 40E 5VR 5VS 67N 6NX 8TC 92F 92I 92L 92M 93N 93R 95- 95. 95~ 96X 9D9 9DE AAAVM AABHQ AAFGU AAHNG AAIAL AAJKR AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABDZT ABECU ABFGW ABFTV ABHQN ABJNI ABJOX ABKAS ABKCH ABKZE ABMNI ABMQK ABNWP ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABWNU ABXPI ACAOD ACBMV ACBRV ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACSNA ACTTH ACVWB ACWMK ACZOJ ADHHG ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFTE AEGAL AEGNC AEJHL AEJRE AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFGCZ AFLOW AFNRJ AFQWF AFUIB AFWTZ AFZKB AGAYW AGDGC AGGBP AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BGNMA CAG CAJEE CAJUS CCEZO CHBEP CIEJG COF CQIGP CS3 CSCUP CW9 DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FA0 FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 HF~ HG6 HLICF HMJXF HRMNR HVGLF HYE HZ~ IAO IEA IHR IJ- IKXTQ IWAJR IXC IXD I~X I~Z J-C JBSCW JUIAU JZLTJ KOV LLZTM M4Y MA- NPVJJ NQJWS NU0 O9- O9J OK1 PF0 PT4 Q-- Q-4 QOR QOS R-E R89 R9I ROL RPM RPX RSV RT5 S.. S16 S1Z S27 S3A S3B SAP SBL SCL SDH SHX SISQX SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW STPWE SV3 SZN T13 T8U TCJ TGQ TSG TUC TUS U1F U1G U2A U5E U5O U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W48 W91 WFFXF WK8 YLTOR Z7U ZMTXR ZOVNA ~A9 ~MX ~WA AACDK AAJBT AASML AAXDM AAYZH ABAKF ACDTI ACPIV AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU BSONS H13 SJYHP AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c502t-f964b314a19715eda329f7b733cb352f9b9cdef389ea8dbc1e3e7d5cd9931d2b3 |
| IEDL.DBID | UNPAY |
| ISSN | 1673-7067 1995-8218 |
| IngestDate | Wed Oct 29 12:15:22 EDT 2025 Tue Sep 30 16:47:24 EDT 2025 Fri Sep 05 12:06:02 EDT 2025 Mon Jul 21 06:04:23 EDT 2025 Wed Oct 01 06:26:45 EDT 2025 Thu Apr 24 22:58:34 EDT 2025 Fri Feb 21 02:33:25 EST 2025 Wed Feb 14 10:34:48 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | 1.5 voltage-dependent blockade Na bupivacaine inactivated state |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-f964b314a19715eda329f7b733cb352f9b9cdef389ea8dbc1e3e7d5cd9931d2b3 |
| Notes | Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels （VGSCs）, how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Navl.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacaine- triggered arrhythmia. Here, we investigated the effect of bupivacaine on Navl.5 within the clinical concentration range. The electrophysiological measurements on Navl.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltage- and concentration-dependent blockade on the peak of/Na and the half-maximal inhibitory dose was 4.51 pmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Navl.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Nay1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine. bupivacaine; Nav1.5; voltage-dependentblockade; inactivated state Heng Zhang, Hui Ji, Zhirui Liu, Yonghua Ji, Xinmin You, Gang Ding, Zhijun Cheng（ 1 Xinhua Hospital Chongming, Shanghai Jiaotong University School of Medicine, Shanghai 202150, China; 2Xinhua Translational Institute for Cancer Pain, Shanghai 202150, China; 3 Lab of Neuropharmacology and Neurotoxicology, Shanghai University, Shanghai 200444, China） 31-1975/R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://link.springer.com/content/pdf/10.1007/s12264-013-1449-1.pdf |
| PMID | 25008571 |
| PQID | 1551017675 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | unpaywall_primary_10_1007_s12264_013_1449_1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5562622 proquest_miscellaneous_1551017675 pubmed_primary_25008571 crossref_primary_10_1007_s12264_013_1449_1 crossref_citationtrail_10_1007_s12264_013_1449_1 springer_journals_10_1007_s12264_013_1449_1 chongqing_primary_662003613 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-08-01 |
| PublicationDateYYYYMMDD | 2014-08-01 |
| PublicationDate_xml | – month: 08 year: 2014 text: 2014-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Heidelberg |
| PublicationPlace_xml | – name: Heidelberg – name: Singapore |
| PublicationTitle | Neuroscience bulletin |
| PublicationTitleAbbrev | Neurosci. Bull |
| PublicationTitleAlternate | Neuroscience Bulletin |
| PublicationYear | 2014 |
| Publisher | Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences |
| Publisher_xml | – name: Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences |
| References | Valenzuela, Sanchez-Chapula (CR4) 1989; 14 Lenkowski, Shah, Dinn, Lee, Patel (CR20) 2003; 467 Hanck, Nikitina, McNulty, Fozzard, Lipkind, Sheets (CR25) 2009; 105 Catterall (CR7) 1995; 64 Gristwood (CR22) 2002; 25 Kindler, Yost (CR17) 2005; 30 Candenas, Seda, Noheda, Buschmann, Cintado, Martin (CR8) 2006; 541 Chen, yang, Zhou, Ji, Zhu (CR19) 2010; 26 Ulbricht (CR26) 2005; 85 Liu, Tao, Dong, Ding, Cheng, He (CR18) 2012; 28 Sakura, Bollen, Ciriales, Drasner (CR16) 1995; 81 Catterall (CR6) 1992; 72 Clarkson, Hondeghem (CR23) 1985; 62 Valenzuela, Snyders, Bennett, Tamargo, Hondeghem (CR11) 1995; 92 Laitinen-Forsblom, Makynen, Makynen, Yli-Mayry, Virtanen, Kontula (CR15) 2006; 17 Graf (CR2) 2001; 1 Wilde, Brugada (CR12) 2011; 108 Eckardt, Kirchhof, Loh, Schulze-Bahr, Johna, Wichter (CR14) 2001; 12 Burlacu, Buggy (CR24) 2008; 4 Brown, Ransom, Hall, Leicht, Schroeder, Offord (CR1) 1995; 81 Wang, Shen, Splawski, Atkinson, Li, Robinson (CR13) 1995; 80 Gonzalez, Longobardo, Caballero, Delpon, Tamargo, Valenzuela (CR5) 2001; 296 Bean, Cohen, Tsien (CR21) 1983; 81 Nau, Wang, Strichartz, Wang (CR9) 1999; 56 Nau, Wang, Wang (CR10) 2003; 63 Ragsdale, McPhee, Scheuer, Catterall (CR3) 1994; 265 BM Graf (1449_CR2) 2001; 1 DS Ragsdale (1449_CR3) 1994; 265 PW Lenkowski (1449_CR20) 2003; 467 Q Wang (1449_CR13) 1995; 80 CH Kindler (1449_CR17) 2005; 30 L Eckardt (1449_CR14) 2001; 12 CW Clarkson (1449_CR23) 1985; 62 RW Gristwood (1449_CR22) 2002; 25 C Nau (1449_CR10) 2003; 63 BP Bean (1449_CR21) 1983; 81 T Gonzalez (1449_CR5) 2001; 296 C Nau (1449_CR9) 1999; 56 WA Catterall (1449_CR6) 1992; 72 DL Brown (1449_CR1) 1995; 81 HW Chen (1449_CR19) 2010; 26 L Candenas (1449_CR8) 2006; 541 C Valenzuela (1449_CR11) 1995; 92 DA Hanck (1449_CR25) 2009; 105 ZR Liu (1449_CR18) 2012; 28 CL Burlacu (1449_CR24) 2008; 4 W Ulbricht (1449_CR26) 2005; 85 S Sakura (1449_CR16) 1995; 81 AA Wilde (1449_CR12) 2011; 108 WA Catterall (1449_CR7) 1995; 64 PJ Laitinen-Forsblom (1449_CR15) 2006; 17 C Valenzuela (1449_CR4) 1989; 14 11405402 - J Cardiovasc Electrophysiol. 2001 Jun;12(6):680-5 20651810 - Neurosci Bull. 2010 Aug;26(4):289-96 2580463 - Anesthesiology. 1985 Apr;62(4):396-405 15898030 - Reg Anesth Pain Med. 2005 May-Jun;30(3):260-74 6306139 - J Gen Physiol. 1983 May;81(5):613-42 21454796 - Circ Res. 2011 Apr 1;108(7):884-97 7586272 - Circulation. 1995 Nov 15;92(10):3014-24 8085162 - Science. 1994 Sep 16;265(5179):1724-8 18728849 - Ther Clin Risk Manag. 2008 Apr;4(2):381-92 1332090 - Physiol Rev. 1992 Oct;72(4 Suppl):S15-48 11895138 - Curr Top Med Chem. 2001 Aug;1(3):207-14 7889574 - Cell. 1995 Mar 10;80(5):805-11 2481194 - J Cardiovasc Pharmacol. 1989 Nov;14(5):783-9 19661462 - Circ Res. 2009 Aug 28;105(5):492-9 16750188 - Eur J Pharmacol. 2006 Jul 10;541(1-2):9-16 11160646 - J Pharmacol Exp Ther. 2001 Feb;296(2):573-83 12761351 - Mol Pharmacol. 2003 Jun;63(6):1398-406 7618726 - Anesth Analg. 1995 Aug;81(2):338-46 12706451 - Eur J Pharmacol. 2003 Apr 25;467(1-3):23-30 16684018 - J Cardiovasc Electrophysiol. 2006 May;17(5):480-5 7574491 - Annu Rev Biochem. 1995;64:493-531 7618723 - Anesth Analg. 1995 Aug;81(2):321-8 10419561 - Mol Pharmacol. 1999 Aug;56(2):404-13 16183913 - Physiol Rev. 2005 Oct;85(4):1271-301 11945112 - Drug Saf. 2002;25(3):153-63 22622820 - Neurosci Bull. 2012 Jun;28(3):209-21 |
| References_xml | – volume: 17 start-page: 480 year: 2006 end-page: 485 ident: CR15 article-title: SCN5A mutation associated with cardiac conduction defect and atrial arrhythmias publication-title: J Cardiovasc Electrophysiol doi: 10.1111/j.1540-8167.2006.00411.x – volume: 108 start-page: 884 year: 2011 end-page: 897 ident: CR12 article-title: Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel publication-title: Circ Res doi: 10.1161/CIRCRESAHA.110.238469 – volume: 26 start-page: 289 year: 2010 end-page: 296 ident: CR19 article-title: Pharmacological modulation of brain Nav1.2 and cardiac Nav1.5 subtypes by the local anesthetic ropivacaine publication-title: Neurosci Bull doi: 10.1007/s12264-010-0122-1 – volume: 265 start-page: 1724 year: 1994 end-page: 1728 ident: CR3 article-title: Molecular determinants of state-dependent block of Na+ channels by local anesthetics publication-title: Science doi: 10.1126/science.8085162 – volume: 63 start-page: 1398 year: 2003 end-page: 1406 ident: CR10 article-title: Point mutations at L1280 in Nav1.4 channel D3-S6 modulate binding affinity and stereoselectivity of bupivacaine enantiomers publication-title: Mol Pharmacol doi: 10.1124/mol.63.6.1398 – volume: 467 start-page: 23 year: 2003 end-page: 30 ident: CR20 article-title: Lidocaine block of neonatal Nav1.3 is differentially modulated by co-expression of beta1 and beta3 subunits publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(03)01595-4 – volume: 80 start-page: 805 year: 1995 end-page: 811 ident: CR13 article-title: SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome publication-title: Cell doi: 10.1016/0092-8674(95)90359-3 – volume: 81 start-page: 613 year: 1983 end-page: 642 ident: CR21 article-title: Lidocaine block of cardiac sodium channels publication-title: J Gen Physiol doi: 10.1085/jgp.81.5.613 – volume: 28 start-page: 209 year: 2012 end-page: 221 ident: CR18 article-title: Pharmacological kinetics of BmK AS, a sodium channel site 4-specific modulator on Nav1.3 publication-title: Neurosci Bull doi: 10.1007/s12264-012-1234-6 – volume: 81 start-page: 321 year: 1995 end-page: 328 ident: CR1 article-title: Regional anesthesia and local anesthetic-induced systemic toxicity: seizure frequency and accompanying cardiovascular changes publication-title: Anesth Analg – volume: 25 start-page: 153 year: 2002 end-page: 163 ident: CR22 article-title: Ca rdiac and CNS toxicity of levobupivacaine: strengths of evidence for advantage over bupivacaine publication-title: Drug Saf doi: 10.2165/00002018-200225030-00002 – volume: 12 start-page: 680 year: 2001 end-page: 685 ident: CR14 article-title: Brugada syndrome and supraventricular tachyarrhythmias: a novel association? publication-title: J Cardiovasc Electrophysiol doi: 10.1046/j.1540-8167.2001.00680.x – volume: 62 start-page: 396 year: 1985 end-page: 405 ident: CR23 article-title: Mechanism for bupivacaine depression of cardiac conduction: fast block of sodium channels during the action potential with slow recovery from block during diastole publication-title: Anesthesiology doi: 10.1097/00000542-198504000-00006 – volume: 81 start-page: 338 year: 1995 end-page: 346 ident: CR16 article-title: Local anesthetic neurotoxicity does not result from blockade of voltage-gated sodium channels publication-title: Anesth Analg – volume: 105 start-page: 492 year: 2009 end-page: 499 ident: CR25 article-title: Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity publication-title: Circ Res doi: 10.1161/CIRCRESAHA.109.198572 – volume: 296 start-page: 573 year: 2001 end-page: 583 ident: CR5 article-title: Effects of bupivacaine and a novel local anesthetic, IQB-9302, on human cardiac K channels publication-title: J Pharmacol Exp Ther – volume: 92 start-page: 3014 year: 1995 end-page: 3024 ident: CR11 article-title: Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes publication-title: Circulation doi: 10.1161/01.CIR.92.10.3014 – volume: 30 start-page: 260 year: 2005 end-page: 274 ident: CR17 article-title: Two-pore domain potassium channels: new sites of local anesthetic action and toxicity publication-title: Reg Anesth Pain Med doi: 10.1016/j.rapm.2004.12.001 – volume: 56 start-page: 404 year: 1999 end-page: 413 ident: CR9 article-title: Point mutations at N434 in D1-S6 of mu1 Na(+) channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers publication-title: Mol Pharmacol – volume: 64 start-page: 493 year: 1995 end-page: 531 ident: CR7 article-title: Structure and function of voltage-gated ion channels publication-title: Annu Rev Biochem doi: 10.1146/annurev.bi.64.070195.002425 – volume: 541 start-page: 9 year: 2006 end-page: 16 ident: CR8 article-title: Molecular diversity of voltage-gated sodium channel alpha and beta subunit mRNAs in human tissues publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2006.04.025 – volume: 85 start-page: 1271 year: 2005 end-page: 1301 ident: CR26 article-title: Sodium channel inactivation: molecular determinants and modulation publication-title: Physiol Rev doi: 10.1152/physrev.00024.2004 – volume: 14 start-page: 783 year: 1989 end-page: 789 ident: CR4 article-title: Electrophysiologic interactions between mexiletine-quinidine and mexiletineropitoin in guinea pig papillary muscle publication-title: J Cardiovasc Pharmacol doi: 10.1097/00005344-198911000-00016 – volume: 1 start-page: 207 year: 2001 end-page: 214 ident: CR2 article-title: The cardiotoxicity of local anesthetics: the place of ropivacaine publication-title: Curr Top Med Chem doi: 10.2174/1568026013395164 – volume: 72 start-page: S15 year: 1992 end-page: 48 ident: CR6 article-title: Cellular and molecular biology of voltage-gated sodium channels publication-title: Physiol Rev – volume: 4 start-page: 381 year: 2008 end-page: 392 ident: CR24 article-title: Update on local anesthetics: focus on levobupivacaine publication-title: Ther Clin Risk Manag – volume: 541 start-page: 9 year: 2006 ident: 1449_CR8 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2006.04.025 – volume: 85 start-page: 1271 year: 2005 ident: 1449_CR26 publication-title: Physiol Rev doi: 10.1152/physrev.00024.2004 – volume: 108 start-page: 884 year: 2011 ident: 1449_CR12 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.110.238469 – volume: 17 start-page: 480 year: 2006 ident: 1449_CR15 publication-title: J Cardiovasc Electrophysiol doi: 10.1111/j.1540-8167.2006.00411.x – volume: 1 start-page: 207 year: 2001 ident: 1449_CR2 publication-title: Curr Top Med Chem doi: 10.2174/1568026013395164 – volume: 4 start-page: 381 year: 2008 ident: 1449_CR24 publication-title: Ther Clin Risk Manag doi: 10.2147/TCRM.S1433 – volume: 30 start-page: 260 year: 2005 ident: 1449_CR17 publication-title: Reg Anesth Pain Med doi: 10.1016/j.rapm.2004.12.001 – volume: 92 start-page: 3014 year: 1995 ident: 1449_CR11 publication-title: Circulation doi: 10.1161/01.CIR.92.10.3014 – volume: 62 start-page: 396 year: 1985 ident: 1449_CR23 publication-title: Anesthesiology doi: 10.1097/00000542-198504000-00006 – volume: 64 start-page: 493 year: 1995 ident: 1449_CR7 publication-title: Annu Rev Biochem doi: 10.1146/annurev.bi.64.070195.002425 – volume: 14 start-page: 783 year: 1989 ident: 1449_CR4 publication-title: J Cardiovasc Pharmacol doi: 10.1097/00005344-198911000-00016 – volume: 265 start-page: 1724 year: 1994 ident: 1449_CR3 publication-title: Science doi: 10.1126/science.8085162 – volume: 25 start-page: 153 year: 2002 ident: 1449_CR22 publication-title: Drug Saf doi: 10.2165/00002018-200225030-00002 – volume: 81 start-page: 321 year: 1995 ident: 1449_CR1 publication-title: Anesth Analg – volume: 105 start-page: 492 year: 2009 ident: 1449_CR25 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.109.198572 – volume: 296 start-page: 573 year: 2001 ident: 1449_CR5 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)38774-9 – volume: 72 start-page: S15 year: 1992 ident: 1449_CR6 publication-title: Physiol Rev doi: 10.1152/physrev.1992.72.suppl_4.S15 – volume: 81 start-page: 613 year: 1983 ident: 1449_CR21 publication-title: J Gen Physiol doi: 10.1085/jgp.81.5.613 – volume: 56 start-page: 404 year: 1999 ident: 1449_CR9 publication-title: Mol Pharmacol doi: 10.1124/mol.56.2.404 – volume: 12 start-page: 680 year: 2001 ident: 1449_CR14 publication-title: J Cardiovasc Electrophysiol doi: 10.1046/j.1540-8167.2001.00680.x – volume: 28 start-page: 209 year: 2012 ident: 1449_CR18 publication-title: Neurosci Bull doi: 10.1007/s12264-012-1234-6 – volume: 81 start-page: 338 year: 1995 ident: 1449_CR16 publication-title: Anesth Analg – volume: 63 start-page: 1398 year: 2003 ident: 1449_CR10 publication-title: Mol Pharmacol doi: 10.1124/mol.63.6.1398 – volume: 80 start-page: 805 year: 1995 ident: 1449_CR13 publication-title: Cell doi: 10.1016/0092-8674(95)90359-3 – volume: 26 start-page: 289 year: 2010 ident: 1449_CR19 publication-title: Neurosci Bull doi: 10.1007/s12264-010-0122-1 – volume: 467 start-page: 23 year: 2003 ident: 1449_CR20 publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(03)01595-4 – reference: 22622820 - Neurosci Bull. 2012 Jun;28(3):209-21 – reference: 11160646 - J Pharmacol Exp Ther. 2001 Feb;296(2):573-83 – reference: 19661462 - Circ Res. 2009 Aug 28;105(5):492-9 – reference: 7618723 - Anesth Analg. 1995 Aug;81(2):321-8 – reference: 16183913 - Physiol Rev. 2005 Oct;85(4):1271-301 – reference: 7618726 - Anesth Analg. 1995 Aug;81(2):338-46 – reference: 15898030 - Reg Anesth Pain Med. 2005 May-Jun;30(3):260-74 – reference: 7586272 - Circulation. 1995 Nov 15;92(10):3014-24 – reference: 8085162 - Science. 1994 Sep 16;265(5179):1724-8 – reference: 7574491 - Annu Rev Biochem. 1995;64:493-531 – reference: 16684018 - J Cardiovasc Electrophysiol. 2006 May;17(5):480-5 – reference: 11945112 - Drug Saf. 2002;25(3):153-63 – reference: 16750188 - Eur J Pharmacol. 2006 Jul 10;541(1-2):9-16 – reference: 7889574 - Cell. 1995 Mar 10;80(5):805-11 – reference: 6306139 - J Gen Physiol. 1983 May;81(5):613-42 – reference: 18728849 - Ther Clin Risk Manag. 2008 Apr;4(2):381-92 – reference: 2481194 - J Cardiovasc Pharmacol. 1989 Nov;14(5):783-9 – reference: 1332090 - Physiol Rev. 1992 Oct;72(4 Suppl):S15-48 – reference: 20651810 - Neurosci Bull. 2010 Aug;26(4):289-96 – reference: 21454796 - Circ Res. 2011 Apr 1;108(7):884-97 – reference: 11405402 - J Cardiovasc Electrophysiol. 2001 Jun;12(6):680-5 – reference: 2580463 - Anesthesiology. 1985 Apr;62(4):396-405 – reference: 12761351 - Mol Pharmacol. 2003 Jun;63(6):1398-406 – reference: 11895138 - Curr Top Med Chem. 2001 Aug;1(3):207-14 – reference: 12706451 - Eur J Pharmacol. 2003 Apr 25;467(1-3):23-30 – reference: 10419561 - Mol Pharmacol. 1999 Aug;56(2):404-13 |
| SSID | ssj0060734 |
| Score | 2.0238976 |
| Snippet | Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its... |
| SourceID | unpaywall pubmedcentral proquest pubmed crossref springer chongqing |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 697 |
| SubjectTerms | Anatomy Anesthesiology Anesthetics, Local - pharmacology Animals Biomedical and Life Sciences Biomedicine Bupivacaine - pharmacology Cells, Cultured Human Physiology NAV1.5 Voltage-Gated Sodium Channel - genetics NAV1.5 Voltage-Gated Sodium Channel - metabolism Neurology Neurosciences Oocytes - metabolism Original Original Article Pain Medicine Voltage-Gated Sodium Channel Blockers - pharmacology Xenopus laevis - genetics Xenopus laevis - metabolism 临床应用 受体结合位点 心脏 毒性反应 电压依赖性 电压门控钠通道 细胞表达 非洲爪蟾卵母细胞 |
| SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELbQVkJcgPJMS5GROFG5al52c6xQSwUqpxYtJ8tPuurWXkjSsvx6xkmcshQV9RxnEtvj8TeamW8Qeku1ENQUJZHGMlJkxpKKWXBcGbVWBcq5LBQnH3-mR6fFx2k5Heq465jtHkOSnaW-LnYLNZ8kdCMAJ6Ai4PKsdXRbE7S2_-Hrp4NogClobRdMpiwnDKxxDGb-S0igVDjz7tt3-ODq1XQDb95MmxxjpyCldQuxvBLz-R_X0-EjdBIn1melnO-0jdxRv_7ifLzjzB-jhwNcxfu9fq2je8Y9QfePh4D8UyS--HkDJonEZroNlnA9ngttsFxi2S5ml0IJGIu9xapTR4Vrr2ftBQ5Fxw7uZmx-dum4RuOZw1Pj_KKtsfdqCTj4GTo9PDh5f0SGrg1ElbtZQ2xFC5mnhUgrlpZGizyrLJMsz5UEtGcrWSltLAAlI_a0VKnJDdOl0oCUUp3J_DmaOO_My1BPDgZbSsCgBbixSlXKCmZkoHSrqGEqQZvj5vFFz87BKQ35doBSErQbt5OrgfA89N2Y82uq5rCwHBaWh4XlaYLeja9EebcMfhN1hMOZDIEW4Yxvax5gKFg68MUS9KLXmVEcQM7QVADeZivaNA4IfN-rT9zsrOP9LgGr0ixL0HZUEz4YnPq2v9weVfP_c9q4k-xN9ADwY9HnQ75Ck-ZHa7YAozXy9XAmfwN-nzJY priority: 102 providerName: Springer Nature |
| Title | Voltage-dependent blockade by bupivacaine of cardiac sodium channels expressed in Xenopus oocytes |
| URI | http://lib.cqvip.com/qk/91222B/201404/662003613.html https://link.springer.com/article/10.1007/s12264-013-1449-1 https://www.ncbi.nlm.nih.gov/pubmed/25008571 https://www.proquest.com/docview/1551017675 https://pubmed.ncbi.nlm.nih.gov/PMC5562622 https://link.springer.com/content/pdf/10.1007/s12264-013-1449-1.pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 30 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1995-8218 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0060734 issn: 1673-7067 databaseCode: AFBBN dateStart: 20070101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1995-8218 dateEnd: 20241105 omitProxy: true ssIdentifier: ssj0060734 issn: 1673-7067 databaseCode: RPM dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1995-8218 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0060734 issn: 1673-7067 databaseCode: AGYKE dateStart: 20070101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1995-8218 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0060734 issn: 1673-7067 databaseCode: U2A dateStart: 20070101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB61iYS48H6EQrRInKjcxq_d-phWDRWoEQeC0pO1zzZqWBtiA-HXM-tXCUVFiJMPXq_t3dmZbzQz3wC8oopzqqPYE9owLwq08RJm0HFl1BjpKOcCV5x8OqUns-jtPJ5vwVFbC1Nlu7chybqmwbE02WI_V2b_qvDN1X96rjMBOgSJh-pGmW3o0xgBeQ_6s-n78ZlztSgLPTaq-shWtcgHaNHa2Oaf5nEMCxeZPf-M79-0VNfg5_Usyi6UirOUNufrb3y5_MVaTe6Cav-zTlK53CsLsSd__EYB-Z8LcQ_uNGiWjGvxuw9b2j6AW6dNvP4h8I_ZskCN5bW9dgsi0HpecqWJWBNR5ouvXHIcSzJDZCWtkqwytSg_EVeTbNF0E_29ytbViiwsmWub5eWKZJlcI0x-BLPJ8YejE69p6uDJeBQUnkloJEI_4n7C_FgrHgaJYYKFoRQIBk0iEqm0QRyl-YES0tehZiqWCoGUrwIRPoaezax-6srNUZ8LgRA1Qi9XykQazrRwjG8J1UwOYKfbzDSvyTtSSl06HoKYAYza7U1lw4fu2nIs0ysmZ7e4KS5u6hY39Qfwunukne-GwS9bmUnxyLo4DLc6K1epQ6moCNFVG8CTWoa66RCRup4D-DTbkK5ugKMD37xjFxcVLXiMUJYGwQB2W7FJG320uukrdztR_fs_Pfun0TtwG-FlVKdLPode8aXULxDCFWII_fHk8HDqrm_O3h0PYXsWjIfNwf0JE3xByA |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQKwEXxJtQHkbiRGWpedn1sUJUC3R76qK9WX7SFYu9kISy_77jbJyyKiriHHuSeMbjbzQznxF6S42U1FY1UdYxUhXWEc4cBK6MOqcj5VwRm5Onp3Qyqz7N6_nQx92kaveUkuw99VWzW-z5JPE2AggCOIGQZzfyV0XC_FlxlNwvBZvtU8mUlYSBL06pzL-JiIQK58F__QGv2z6YrqHN60WTY-YUpHR-JdcXcrn843A6vo_uDagSH23M4AG6Zf1DdHs65M0fIfklLFvwHCTdedtiBafYN2ksVmusutXil9QSxuLgsO6tRuMmmEX3HcfeYA9HKLa_-6pZa_DC47n1YdU1OAS9Brj6GM2OP5y9n5DhcgWi64OiJY7TSpV5JXPO8toaWRbcMcXKUisAZY4rro11gGesPDRK57a0zNTaAKDJTaHKJ2jHB2-fxbZv8KtKAVSsINrUmmsnmVWReY1Ty3SG9sZVFqsNiYagNJbFAZjI0EFad6EHXvJ4PcZSXDEqR7UJUJuIahN5ht6NU5K8Gwa_ScoUsHViPkR6G7pGRLQIDglCpgw93Sh3FAfIMHL_w2y2pfZxQKTl3n7iF-c9PXcNkJIWRYb2k4GIwS80N33l_mhD__6n5_8l-zW6MzmbnoiTj6ef99BdgHzVpoTxBdppf3b2JcCqVr3qt9El3acYeg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQK1VcEG9CeRiJE5XV5mXjY1VYlUcrDizam-UnXbE4gSTQ_fcdJ3HKqqiIc5xJ4pmMv9HMfIPQS2qkpLYoibKOkSKzjnDmIHBl1DkdKOey0Jx8ckqP58X7RbkY55w2sdo9piSHnobA0uTb_dq4_cvGt9D_ScJkAggIOIHwZ7sIPAlg0PPsMLpiCvbbp5UpywkDvxzTmn8TEcgVzir_9Qc8evOQuoI8rxZQTllUkNL5Wq5_y9Xqj4NqdhvdGhEmPhxM4g66Yf1dtHMy5tDvIfmlWrXgRUicf9tiBSfaN2ksVmusunr5S2oJa3HlsO4tSOOmMsvuOw59wh6OU2zP-wpaa_DS44X1Vd01uKr0GqDrfTSfvf18dEzGQQtElwdZSxynhcrTQqacpaU1Ms-4Y4rluVYA0BxXXBvrANtY-doondrcMlNqA-AmNZnKH6AtX3n7KLSAg49VCmBjAZGn1lw7yawKLGycWqYTtDvtsqgHQg1BaSiRA2CRoIO470KPHOVhVMZKXLIrB7UJUJsIahNpgl5Nt0R51yx-EZUp4DcKuRHpbdU1IiBHcE4QPiXo4aDcSRygxDAHAO5mG2qfFgSK7s0rfnnWU3WXAC9pliVoLxqIGH1Ec91b7k029O9vevxfsp-jnU9vZuLju9MPu-gmoL9iqGZ8grban519CgirVc_6v-gCsLgctg |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VrYS4lHdZCshInKjcbl52c6wqqgqpFQcWLSfLT7rq4qRsAiy_nnFeZSkqQpxjO4k9nvlGM_MNwCtmpGQ2zaiyjtM0to7m3KHjyplzOlDOxaE4-fSMnUzTt7NstgFHfS1Mk-3ehyTbmobA0uSr_dK4_avCt1D_SUNnAnQIcorqxrhbsMkyBOQj2JyevTv8GFwtxhPKJ00f2aYW-QAtWh_b_NM6gWHhvPCfLvH965bqGvy8nkU5hFJxldqXcvVNLha_WKvju2D6_2yTVC726krt6R-_UUD-50bcg60OzZLDVvzuw4b1D-D2aRevfwjyQ7GoUGPRvtduRRRazwtpLFEroupy_lVqiWNJ4YhupFWTZWHm9WcSapI9mm5ivzfZutaQuScz64uyXpKi0CuEyY9gevzm_dEJ7Zo6UJ1N4oq6nKUqiVIZ5TzKrJFJnDuueJJohWDQ5SrXxjrEUVYeGKUjm1huMm0QSEUmVsljGPnC2yeh3Bz1uVIIUVP0crXOtZPcqsD4ljPL9Rh2hsMUZUveIRgL6XgIYsYw6Y9X6I4PPbTlWIgrJuewuQI3V4TNFdEYXg9T-vVuGPyylxmBVzbEYaS3Rb0UAaWiIkRXbQzbrQwNyyEiDT0HcDZfk65hQKADX3_i5-cNLXiGUJbF8Rh2e7ERnT5a3vSVu4Oo_v2fnv7T6B24g_AybdMln8Go-lLb5wjhKvWiu6I_AZ20Pc8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Voltage-dependent+blockade+by+bupivacaine+of+cardiac+sodium+channels+expressed+in+Xenopus+oocytes&rft.jtitle=Neuroscience+bulletin&rft.au=Zhang%2C+Heng&rft.au=Ji%2C+Hui&rft.au=Liu%2C+Zhirui&rft.au=Ji%2C+Yonghua&rft.date=2014-08-01&rft.issn=1673-7067&rft.eissn=1995-8218&rft.volume=30&rft.issue=4&rft.spage=697&rft.epage=710&rft_id=info:doi/10.1007%2Fs12264-013-1449-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12264_013_1449_1 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91222B%2F91222B.jpg |